| 发明名称 |
Pharmaceutical diagnostic |
| 摘要 |
<p>The invention is directed, in part, to selective cancer treatment regimes based on assaying for the presence or absence of a mutation in a nucleic acid that encodes glutamine at position 859 of the catalytic p110αsubunit of PI3K.</p> |
| 申请公布号 |
AU2013241752(A1) |
申请公布日期 |
2014.09.25 |
| 申请号 |
AU20130241752 |
申请日期 |
2013.03.27 |
| 申请人 |
NOVARTIS AG |
发明人 |
FURET, PASCAL;FRITSCH, CHRISTINE;MAIRA, SAUVEUR-MICHEL |
| 分类号 |
A61K31/4439;A61P35/00;C12N15/11;C12Q1/68;G11B20/00 |
主分类号 |
A61K31/4439 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
